Impact of gantenerumab amyloid removal therapy on established Alzheimer Disease fluid biomarkers
Impact of gantenerumab amyloid removal therapy on established Alzheimer Disease fluid biomarkers
About this item
Full title
Author / Creator
Ibanez, Laura , Li, Yan , McDade, Eric , Llibre‐Guerra, Jorge J. , Clifford, David B. , Mills, Susan , Santacruz, Anna , Wang, Guoqiao , Supnet‐Bell, Charlene , Benzinger, Tammie L.S. , Gordon, Brian A. , Klein, Gregory , Baudler, Monika , Doody, Rachelle S. , Kerchner, Geoffrey A. , Bittner, Tobias , Atri, Alireza and Bateman, Randall J.
Publisher
Hoboken: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Background
Anti‐amyloid monoclonal antibody therapies have successfully removed amyloid plaque as measured using imaging techniques. However, the characteristic fluid biomarker trajectories following plaque removal remains understudied, particularly during the preclinical phases of disease. We investigated biomarker trajectories in the context o...
Alternative Titles
Full title
Impact of gantenerumab amyloid removal therapy on established Alzheimer Disease fluid biomarkers
Authors, Artists and Contributors
Author / Creator
Li, Yan
McDade, Eric
Llibre‐Guerra, Jorge J.
Clifford, David B.
Mills, Susan
Santacruz, Anna
Wang, Guoqiao
Supnet‐Bell, Charlene
Benzinger, Tammie L.S.
Gordon, Brian A.
Klein, Gregory
Baudler, Monika
Doody, Rachelle S.
Kerchner, Geoffrey A.
Bittner, Tobias
Atri, Alireza
Bateman, Randall J.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713540
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713540
Other Identifiers
ISSN
1552-5260
E-ISSN
1552-5279
DOI
10.1002/alz.094831
